Novo Nordisk faces Capitol Hill scrutiny for pulling Levemir insulin off the market

US Senate aides will meet with Novo Nordisk executives on Tuesday to discuss the consequences of its decision to stop selling one of its long-acting insulins in the country. In April, lawmakers wrote to the company expressing alarm over its decision to permanently discontinue Levemir at the end of 2024.

Share This Post:

POPULAR POSTS
FOLLOW US
Like Us On Facebook
Follow Us On Twitter
Subscribe To Our Channel
TikTok
LIVE STREAM